SV Life Sciences
United States of America
Mr. Burgess is Venture Partner at SV Life Sciences. Previously, he was President and Chief Executive Officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders.
infectious diseases, and immune system disorders.